Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-16673 versus investigator's choice in previously BTK- and BCL2-exposed CLL/SLL
2024-518893-15-00Phase 3Authorised
- Sponsor
- BeOne Medicines
- Start
- Jul 2025
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial of catadegbrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (4 arms), sponsored by BeOne Medicines. Primary endpoint: Progression-free survival. Planned start Jul 2025; status: authorised.
02
Drugs
catadegbrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2024-518893-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518893-15-00.